Animal models of multiple myeloma and their utility in drug discovery.
Animal models of multiple myeloma and their utility in drug discovery.
复制标题
DOI：
10.1002/0471141755.ph1409s40
复制
发表时间：
2008-03-01
影响因子：
--
通讯作者：
Berenson, James R
中科院分区：
文献类型：
--
作者：
Campbell, Richard A;Berenson, James R
为了评价治疗多发性骨髓瘤（MM）的潜在新疗法和靶点，需要可重复的、生物学相关的体内模型。人类MM的临床前体内模型允许研究人员评估单独和联合的新疗法，并将这些结果快速转化为患者直接受益的临床，无论是新的临床试验，新的剂量和时间表，还是新的药物组合。本单元介绍了在小鼠中产生和维持人髓外MM肿瘤的方案。另外，可以切除髓外肿瘤并消化成单细胞悬浮液，并将人MM细胞皮下、静脉内或胫骨内注射到小鼠中。一旦这些肿瘤产生，它们可用于评估新型抗MM药物和其他疗法。
To evaluate potential new therapies and targets for treating multiple myeloma (MM), reproducible, biologically relevant in vivo models are required. Preclinical in vivo models of human MM allow investigators to evaluate novel therapies alone and in combination and quickly translate these results to the clinic where patients directly benefit, whether in the form of a new clinical trial, new doses and schedules, or new drug combinations. Presented in this unit are protocols for generating and maintaining a human extramedullary MM tumor in mice. Additionally, the extramedullary tumor can be excised and digested into a single-cell suspension and the human MM cells injected into mice subcutaneously, intravenously, or intratibially. Once these tumors are generated, they can be used to evaluate novel anti-MM agents and other therapies.